- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Bristol Myers Squibb Downgraded to Buy Rating
Wall Street Zen cites concerns over the pharmaceutical company's recent earnings report
Apr. 12, 2026 at 8:19am
Got story updates? Submit your updates here. ›
The inner workings of Bristol Myers Squibb's manufacturing operations reflect the company's financial and operational challenges.Princeton TodayWall Street Zen has downgraded shares of Bristol Myers Squibb (NYSE: BMY) from a strong-buy rating to a buy rating in a new report published on Saturday. The report cites Bristol Myers Squibb's recent earnings miss as a key factor behind the rating change.
Why it matters
Bristol Myers Squibb is one of the world's largest pharmaceutical companies, so changes to its stock rating can have significant implications for investors and the broader healthcare industry. The downgrade from Wall Street Zen reflects concerns about the company's financial performance and future outlook.
The details
In its report, Wall Street Zen noted that Bristol Myers Squibb reported earnings per share of $1.26 for the most recent quarter, missing the consensus estimate of $1.65. The company also provided full-year 2026 guidance in the range of $6.05 to $6.35 per share, which was lower than analyst expectations. Several other brokerages, including Leerink Partners, Wells Fargo, and Piper Sandler, have also recently adjusted their ratings and price targets for Bristol Myers Squibb.
- Bristol Myers Squibb reported Q4 2025 earnings on February 5, 2026.
- The company's Q1 2026 earnings are expected to be reported in early May 2026.
The players
Wall Street Zen
A financial research and analysis firm that provides investment ratings and recommendations.
Bristol Myers Squibb
A global biopharmaceutical company focused on developing and delivering medicines for serious diseases, with a strong emphasis on cancer and immune-mediated conditions.
What’s next
Investors will be closely watching Bristol Myers Squibb's upcoming Q1 2026 earnings report in early May to see if the company can rebound from the recent earnings miss.
The takeaway
The downgrade of Bristol Myers Squibb by Wall Street Zen highlights the importance of pharmaceutical companies consistently meeting or exceeding investor expectations. The company's ability to navigate the competitive healthcare landscape and deliver strong financial results will be crucial in the coming quarters.
